Viatris to Report Q1 2026 Financial Results on May 7
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VTRS?
Source: PRnewswire
- Earnings Release Schedule: Viatris Inc. will report its Q1 2026 financial results on May 7, 2026, showcasing the company's performance and developments in the global healthcare sector.
- Webcast Conference: Company executives will host a webcast at 8:30 AM ET on the same day, allowing investors and the public to participate, thereby enhancing transparency and engagement.
- Replay Availability: A replay of the webcast will be available post-earnings release, ensuring that investors who cannot attend live can access key information, thus improving information accessibility.
- Company Mission and Vision: Viatris is committed to meeting global patient needs through innovation and resolute decision-making, demonstrating its strategic positioning and market impact within the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTRS
Wall Street analysts forecast VTRS stock price to fall
4 Analyst Rating
2 Buy
1 Hold
1 Sell
Hold
Current: 13.610
Low
10.00
Averages
13.25
High
16.00
Current: 13.610
Low
10.00
Averages
13.25
High
16.00
About VTRS
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viatris to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Viatris Inc. will report its Q1 2026 financial results on May 7, 2026, showcasing the company's performance and developments in the global healthcare sector.
- Webcast Conference: Company executives will host a webcast at 8:30 AM ET on the same day, allowing investors and the public to participate, thereby enhancing transparency and engagement.
- Replay Availability: A replay of the webcast will be available post-earnings release, ensuring that investors who cannot attend live can access key information, thus improving information accessibility.
- Company Mission and Vision: Viatris is committed to meeting global patient needs through innovation and resolute decision-making, demonstrating its strategic positioning and market impact within the pharmaceutical industry.
See More
Viatris Presents Four Studies at ASCRS Annual Meeting
- Research Presentation: Viatris will present four studies at the 2026 ASCRS Annual Meeting, including full results from the VEGA-3 Phase 3 study of MR-141, indicating its potential in treating presbyopia, which could enhance the company's position in the ophthalmology market.
- New Drug Research: The company will also showcase results from a Phase 1 study of varenicline nasal spray in healthy Japanese adults, demonstrating its potential application in improving visual function, which may open new market opportunities in the future.
- Visual Disturbance Analysis: An encore presentation of the LYNX-2 Phase 3 study highlights MR-142's effectiveness in improving visual disturbances under low-light conditions, emphasizing the drug's significance for post-refractive surgery patients and potentially strengthening Viatris's competitive edge in this area.
- Educational Support Initiative: Viatris provided independent funding for an educational symposium hosted by PRIME, aimed at fostering peer exchange and supporting the management of presbyopia, reflecting the company's commitment to advancing education and innovation in the ophthalmology field.
See More
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor® SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare, becoming the first and only approved treatment for adults with generalized anxiety disorder (GAD) in Japan, addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Market Demand Response: With approximately 7.6% of the Japanese population potentially suffering from GAD, this approval not only provides a new treatment option for patients but also has the potential to reduce social and occupational impairments caused by anxiety, thereby enhancing overall societal productivity.
- Clinical Trial Success: The approval of Effexor® is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated significant anxiolytic effects of venlafaxine compared to placebo at 8 weeks, as measured by the Hamilton Anxiety Rating Scale (HAM-A), with all seven secondary efficacy endpoints met.
- Strategic Investment and Expansion: This approval marks the successful execution of Viatris' innovative product portfolio strategy in Japan, and the company plans to leverage its deep expertise in central nervous system therapies to further expand its market presence and meet urgent patient needs.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor®SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare as the first and only treatment option for adults with generalized anxiety disorder (GAD), addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Successful Clinical Trials: The approval is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated that Effexor® significantly outperformed placebo over 8 weeks, achieving statistical significance in the change of Hamilton Anxiety Rating Scale total score (p-value=0.012), providing a solid foundation for market promotion.
- Huge Market Potential: With a reported GAD prevalence of 7.6% in Japan, the demand for this medication is substantial, and Viatris plans to leverage its deep expertise in central nervous system therapies to enhance Effexor®'s market penetration and strengthen its competitive position in the mental health sector.
- Strategic Investment and Innovation: This approval aligns with Viatris' innovative product portfolio in Japan, showcasing the company's strategic execution in addressing unmet medical needs, and it will continue to drive the development of more innovative therapies to tackle health challenges in the Japanese market.
See More
Viatris Sets Long-Term Financial Targets Through 2030
- Long-Term Financial Goals: Viatris (VTRS) aims for a total revenue CAGR of 5%-6% through 2030, with adjusted EBITDA and EPS growth projected at 7%-8% and 9%-10%, respectively, reflecting the company's confidence in future growth.
- Base Business Forecast: For its base business, Viatris anticipates a total revenue CAGR of 3%-4%, adjusted EBITDA of 4%-5%, and adjusted EPS of 6%-7%, providing a solid foundation for sustainable growth.
- Cost Savings Initiative: The company expects to achieve $650 million in gross cost savings over three years from a recently completed enterprise-wide strategic review, which will support adjusted EBITDA growth through operational leverage.
- Cash Flow Outlook: Viatris projects over $2.7 billion in annual free cash flow by 2030 and more than $11 billion in cash available for deployment through 2030, indicating strong financial flexibility and investment potential.
See More
Viatris to Report Q1 2026 Financial Results on May 7
- Earnings Release Schedule: Viatris Inc. will report its Q1 2026 financial results on May 7, 2026, showcasing the company's performance and developments in the global healthcare sector.
- Webcast Conference: Company executives will host a webcast at 8:30 AM ET on the same day, allowing investors and the public to participate, thereby enhancing transparency and engagement.
- Replay Availability: A replay of the webcast will be available post-earnings release, ensuring that investors who cannot attend live can access key information, thus improving information accessibility.
- Company Mission and Vision: Viatris is committed to meeting global patient needs through innovation and resolute decision-making, demonstrating its strategic positioning and market impact within the pharmaceutical industry.
See More
Viatris Presents Four Studies at ASCRS Annual Meeting
- Research Presentation: Viatris will present four studies at the 2026 ASCRS Annual Meeting, including full results from the VEGA-3 Phase 3 study of MR-141, indicating its potential in treating presbyopia, which could enhance the company's position in the ophthalmology market.
- New Drug Research: The company will also showcase results from a Phase 1 study of varenicline nasal spray in healthy Japanese adults, demonstrating its potential application in improving visual function, which may open new market opportunities in the future.
- Visual Disturbance Analysis: An encore presentation of the LYNX-2 Phase 3 study highlights MR-142's effectiveness in improving visual disturbances under low-light conditions, emphasizing the drug's significance for post-refractive surgery patients and potentially strengthening Viatris's competitive edge in this area.
- Educational Support Initiative: Viatris provided independent funding for an educational symposium hosted by PRIME, aimed at fostering peer exchange and supporting the management of presbyopia, reflecting the company's commitment to advancing education and innovation in the ophthalmology field.
See More
VIATRIS INC.: BARCLAYS INCREASES TARGET PRICE FROM $15 TO $17
Company Announcement: Viasat Inc. has announced that Barclays has raised its price target for the company's stock.
New Price Target: The new price target for Viasat's stock is set at $17, an increase from the previous target of $15.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor® SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare, becoming the first and only approved treatment for adults with generalized anxiety disorder (GAD) in Japan, addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Market Demand Response: With approximately 7.6% of the Japanese population potentially suffering from GAD, this approval not only provides a new treatment option for patients but also has the potential to reduce social and occupational impairments caused by anxiety, thereby enhancing overall societal productivity.
- Clinical Trial Success: The approval of Effexor® is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated significant anxiolytic effects of venlafaxine compared to placebo at 8 weeks, as measured by the Hamilton Anxiety Rating Scale (HAM-A), with all seven secondary efficacy endpoints met.
- Strategic Investment and Expansion: This approval marks the successful execution of Viatris' innovative product portfolio strategy in Japan, and the company plans to leverage its deep expertise in central nervous system therapies to further expand its market presence and meet urgent patient needs.
See More
Japan Approves First Treatment for Generalized Anxiety Disorder
- First Approved Drug: Viatris' Effexor®SR 37.5 mg / 75 mg capsules have been approved by Japan's Ministry of Health, Labour and Welfare as the first and only treatment option for adults with generalized anxiety disorder (GAD), addressing a long-standing unmet medical need and expected to significantly improve patients' quality of life.
- Successful Clinical Trials: The approval is based on a Phase 3 randomized double-blind clinical trial conducted in Japan, which demonstrated that Effexor® significantly outperformed placebo over 8 weeks, achieving statistical significance in the change of Hamilton Anxiety Rating Scale total score (p-value=0.012), providing a solid foundation for market promotion.
- Huge Market Potential: With a reported GAD prevalence of 7.6% in Japan, the demand for this medication is substantial, and Viatris plans to leverage its deep expertise in central nervous system therapies to enhance Effexor®'s market penetration and strengthen its competitive position in the mental health sector.
- Strategic Investment and Innovation: This approval aligns with Viatris' innovative product portfolio in Japan, showcasing the company's strategic execution in addressing unmet medical needs, and it will continue to drive the development of more innovative therapies to tackle health challenges in the Japanese market.
See More
Viatris Sets Long-Term Financial Targets Through 2030
- Long-Term Financial Goals: Viatris (VTRS) aims for a total revenue CAGR of 5%-6% through 2030, with adjusted EBITDA and EPS growth projected at 7%-8% and 9%-10%, respectively, reflecting the company's confidence in future growth.
- Base Business Forecast: For its base business, Viatris anticipates a total revenue CAGR of 3%-4%, adjusted EBITDA of 4%-5%, and adjusted EPS of 6%-7%, providing a solid foundation for sustainable growth.
- Cost Savings Initiative: The company expects to achieve $650 million in gross cost savings over three years from a recently completed enterprise-wide strategic review, which will support adjusted EBITDA growth through operational leverage.
- Cash Flow Outlook: Viatris projects over $2.7 billion in annual free cash flow by 2030 and more than $11 billion in cash available for deployment through 2030, indicating strong financial flexibility and investment potential.
See More
